Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 855-863

  Lewis, Kriste A ^a   Lilly, Kia K ^a   Reynolds, Evelyn A ^a   Sullivan, William P ^a   Kaufmann, Scott H ^a   Cliby, William A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ATR PROTEIN; CISPLATIN; MELPHALAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; ATR PROTEIN, HUMAN; CELL CYCLE PROTEIN; PLATINUM COMPLEX; PROTEIN SERINE THREONINE KINASE;

ALLELE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DNA ADDUCT; DNA CROSS LINKING; DRUG SENSITIVITY; ENZYME INDUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; BONE TUMOR; CHROMATIN; DNA REPAIR; DOMINANT GENE; DRUG EFFECT; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; OSTEOSARCOMA; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE PROTEINS; CELL SURVIVAL; CHROMATIN; CISPLATIN; DNA ADDUCTS; DNA REPAIR; FLOW CYTOMETRY; GENES, DOMINANT; HUMANS; ORGANOPLATINUM COMPOUNDS; OSTEOSARCOMA; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; S PHASE; TUMOR CELLS, CULTURED;

EID: 66449095927     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1135     Document Type: Article

References (50)

1. Brabec V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol 2002;71:1-68.
2. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev 2007;7:573-584
3. Pera MF, Jr., Rawlings CJ, Roberts JJ. The role of DNA repair in the recovery of human cells from cisplatin toxicity. Chem Biol Interact 1981; 37:245-261
4. Fitchinger-Schepman AM, Lohman PH, Berends F, Reedijk J, van Oosterom AT. Interactions of the antitumour drug cisplatin with DNA in vitro and in vivo. IARC Sci Publ 1986;78:83-99.
5. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998;54:770-777 (Pubitemid 28523169)
6. Saris CP, van de Vaart PJ, Rietbroek RC, Blommaert FA. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996;17:2763-2769
7. Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000;58:920-927
8. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 2000;35:75-93. (Pubitemid 30599431)
9. Hoffmann JS, Pillaire MJ, Maga G, Podust V, Hubscher U, Villani G. DNA polymerase β bypasses in vitro a single d(gpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad Sci U S A 1995;92:5356-5360
10. Vaisman A, Lim SE, Patrick SM, et al. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry (Mosc) 1999;38:11026-11039 (Pubitemid 129752903)
11. Canitrot Y, Cazaux C, Frechet M, et al. Overexpression of DNA polymerase β in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A 1998;95:12586-12590 (Pubitemid 28483808)
12. Vaisman A, Chaney SG. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase β. J Biol Chem 2000;275:13017-13025 (Pubitemid 30241462)
13. Voland C, Bord A, Peleraux A, et al. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 2006;5:2149-2157 (Pubitemid 44530450)
14. Perego P, Zunino F, Carenini N, Giuliani F, Spinelli S, Howell SB. Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants. Mol Pharmacol 1998;54:213-219 (Pubitemid 28337605)
15. Simon JA, Szankasi P, Nguyen DK, et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 2000;60:328-333 (Pubitemid 30070759)
16. Damia G, Filiberti L, Vikhanskaya F, et al. Cisplatinum and Taxol induce different patterns of p53 phosphorylation. Neoplasia 2001;3:10-16 (Pubitemid 32201605)
17. Yazlovitskaya EM, Persons DL. Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. Anticancer Res 2003;23:2275-2279 (Pubitemid 36897091)
18. Tibbetts RS, Cortez D, Brumbaugh KM, et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 2000;14:2989-3002.
19. Sorensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005;7:195-201. (Pubitemid 40268135)
20. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-23903 (Pubitemid 30624678)
21. Cliby WA, Roberts CJ, Cimprich KA, et al. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 1998;17:159-169 (Pubitemid 28041057)
22. Nghiem P, Park PK, Kim Ys YS, Desai BN, Schreiber SL. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem 2002;277:4428-4434 (Pubitemid 34968710)
23. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 2005;314:495-505. (Pubitemid 41043829)
24. Nojima K, Hochegger H, Saberi A, et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 2005;65:11704-11711 (Pubitemid 41821731)
25. Wilsker D, Bunz F. Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol Cancer Ther 2007;6:1406-1413 (Pubitemid 46712004)
26. 1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A 2001;98:9092-9097
27. Armstrong DK, Kaufmann SH, Ottaviano YL, et al. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res 1994;54:5280-5283 (Pubitemid 24336014)
28. Budihardjo II, Walker DL, Svingen PA, et al. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res 1998;4:117-130 (Pubitemid 28062885)
29. Budihardjo II, Boerner S, Eckdahl S, et al. Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity. Mol Pharmacol 2000;57:529-538 (Pubitemid 30140883)
30. Walker DL, Reid JM, Svingen PA, et al. Murine pharmacokinetics of 6-aminonicotinamide, a novel biochemical modulating agent. Biochem Pharmacol 1999;58:1057-1066 (Pubitemid 29361472)
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254
32. 2 arrests induced by Topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 2002;277:1599-1606
33. Mendez J, Stillman B. Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. Mol Cell Biol 2000;20:8602-8612
34. Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997;3:1034-1036 (Pubitemid 27391962)
35. Ellison V, Stillman B. Biochemical characterization of DNA damage checkpoint complexes: clamp loader and clamp complexes with specificity for 5′ recessed DNA. PLoS Biol 2003;1:E33. (Pubitemid 39112165)
36. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003;300:1542-1548 (Pubitemid 36682880)
37. 1-S and in G2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro. J Cancer Res Clin Oncol 1983;106:44-52.
38. Sorenson CM, Eastman A. Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 1988;48:6703-6707 (Pubitemid 19012192)
39. 2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-797
40. Lee SI, Brown MK, Eastman A. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol 1999;58:1713-1721 (Pubitemid 29505411)
41. 2 after cisplatin treatment. Mutat Res 2000;461:1-13.
42. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-2196 (Pubitemid 32843830)
43. Wang H, Wang H, Powell SN, Iliakis G, Wang Y. ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res 2004;64:7139-7143 (Pubitemid 39331028)
44. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31. (Pubitemid 46810280)
45. Bible KC, Boerner SA, Kirkland K, et al. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res 2000;6:661-670 (Pubitemid 30111492)
46. Dart DA, Adams KE, Akerman I, Lakin ND. Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S-phase. J Biol Chem 2004;279:16433-16440 (Pubitemid 38509341)
47. Delacroix S, Wagner JM, Kobayashi M, Yamamoto K, Karnitz LM. The Rad9-1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. Genes Dev 2007;21:1472-1477 (Pubitemid 46955719)
48. Menoyo A, Alazzouzi H, Espin E, Armengol M, Yamamoto H, Schwartz S, Jr. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 2001;61:7727-7730
49. Vassileva V, Millar A, Briollais L, Chapman W, Bapat B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 2002;62:4095-4099 (Pubitemid 34791080)
50. Lewis KA, Mullany S, Thomas B, et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res 2005;65:7091-7095 (Pubitemid 41161237)